Mechanisms, Predictors, and Challenges in Assessing and Managing Painful Chemotherapy-induced Peripheral Neuropathy

Ítems similars

• The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure
  per: Lavoie Smith, Ellen M., et al.
  Publicat: (2017)
• In Search of a Gold Standard Patient-Reported Outcome Measure for Use in Chemotherapy- Induced Peripheral Neuropathy Clinical Trials
  per: Smith, Ellen M. Lavoie, et al.
  Publicat: (2018)
• Characterization of Internal Validity Threats to Phase III Clinical Trials for Chemotherapy-Induced Peripheral Neuropathy Management: A Systematic Review
  per: Lee, Deborah, et al.
  Publicat: (2019)
• Assessment of Pediatric Chemotherapy-Induced Peripheral Neuropathy Using a New Patient-Reported Outcome Measure: The P-CIN
  per: Smith, Ellen M. Lavoie, et al.
  Publicat: (2020)
• Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire–Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data
  per: Smith, Ellen M. Lavoie, et al.
  Publicat: (2018)